



**Poster Session A**  
**Sunday, December 3, 2017**  
**4:30 p.m. - 6:30 p.m.**  
**Salons IV-VI & Marvin Gardens and Marvin Gardens Patio**

**A002 Comparison of circulating microRNAs in plasma before and after radical prostatectomy among men treated for prostate cancer.** Alicia C McDonald, Jay D Raman, Jing Shen, Jason Liao, Manish Vira.

**A003 Epigenetic alterations as potential biological determinants of racial health disparities.** Swathi Ramakrishnan, Peng Xuan, Qianya Qi, Qiang Hu, Emily Ellman, Gissou Azabdaftari, Elena Pop, James Mohler, Kristopher Attwood, Yan Li, Jianmin Wang, Anna Woloszynska-Read.

**A004 MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo anti-tumor activity in prostate cancer patient-derived xenograft models.** Song Cho, Francesca Zammarchi, Noel R Monks, Kapil Vashisht, Ravinder Tammali, Kevin Schifferli, Patrick Strout, Wanda King, Karma Dacosta, Ryan Fleming, David G Williams, Karin Havenith, Mary Jane Masson Hinrichs, Simon Chivers, Nazzareno Dimasi, Phil W Howard, John A Hartley, Steve Coats, Ronald Herbst, Patrick H van Berkel, David A Tice.

**A005 Patterns in Distant Metastasis at Diagnosis in a Racially Diverse, Longitudinal Cohort of Prostate Cancer Patients: 1989-2013.** John McCauley, Huai-Ching Kuo, Inger L Rosner, Yongmei Chen, Lauren Hurwitz, Sean Stroup, Joseph R Sterbis, Christopher Porter, Timothy C Brand, Shiv Srivastava, Jennifer Cullen.

**A006 Skp2 associates with Slug and androgen receptor in aggressive prostate cancer.** Jan Bouchal, Gvantsa Kharashvili, Alena Mickova, Mariam Gachechiladze, Alena Burdova, Martin Mistrik, Milan Kral, Balazs Gyorffy, Zdenek Kolar.

**A007 Methyl jasmonate and finasteride synergistically reduce testosterone-induced benign prostatic hyperplasia through regulation of inflammatory and apoptotic processes in rats.** Oluwatosin A Adaramoye, Solomon E Owumi, Olubukola Akanni, Oluwabunmi E Olapade-Olaopa, Olusoji J Abiola, Oluyemi Akinloye.

**A008 Intraprostatic cell cycle proteins in relation to the risk of prostate cancer recurrence.** Michael Cook, Sarah Daugherty, Petra Lenz, Laufey Amundadottir, Lawrence Sternberg, Joshua Sampson, Sally Coburn, Wen-Yi Huang, Neal Freedman, Amanda Black, Sonja Berndt, Stephen Hewitt, Robert Hoover.

**A009 The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer.** Richard Rebello, Eric Kusnadi, Donald P Cameron, Pearson Helen, Denis Drygin, Shahneen Sandhu, Gail Risbringer, Richard B Pearson, Ross D Hannan, Luc Furic.

**A010 ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress**

**in Prostate Cancer Development.** Taduru L Sreenath, Shiela S Macalindong, Natallia Mikhalkevich, Shashwat Sharad, Ahmed Mohamed, Denise Young, Borbiev Talaipek, Charles Xavier, Rishita Gupta, Muhammad Jamal, Kevin Babcock, Shyh-Han Tan Tan, Marja T Nevalainen, Albert Dobi, Gyorgy Petrovics, Isabell A Sesterhenn, Inger L Rosner, Charles J Bieberich, Peter Nelson, Valeri Vasioukhin, Shiv Srivastava.

**A011 Hypoxia-inducible PIM kinase expression promotes resistance to anti-angiogenic agents in prostate cancer.** Andrea Casillas, Rachel Toth, Alva Sainz, Andrew S Kraft, Noel A Warfel.

**A012 MiR-96 targets retinoic acid receptor gamma cross-talk with the androgen receptor to drive aggressive prostate cancer.** Mark D Long, Spencer Rosario, Lara S Ucheston-Campbell, Dominic Smiraglia, Moray J Campbell.

**A013 Prostate cancer gene expression panel to address racial differences of molecular alterations in prostate cancer.** Indu kohaar, Sreedatta Banerjee, Lakshmi Ravindranath, Yongmei Chen, Amina Ali, Jacob Kagan, Sudhir Srivastava, Albert Dobi, David McLeod, Inger Rosner, Shiv Srivastava, Gyorgy Petrovics.

**A014 Raman microscopy to assess biochemical recurrence risk after radical prostatectomy.** Andrée-Anne Grosset, Catherine St-Pierre, Karl St-Arnaud, Kelly Aubertin, Michael Jermyn, Frédéric Leblond, Dominique Trudel.

**A015 Molecular tumor profiling to identify mechanisms linking statin use with lower risk of lethal prostate cancer; results from the Health Professionals Follow-up Study.** Emma H Allott, Ericka M Ebot, Amparo G Gonzalez-Feliciano, Sarah C Markt, Kathryn M Wilson, Thomas U Ahearn, Travis A Gerke, Mary K Downer, Konrad H Stopsack, Jennifer R Rider, Stephen J Freedland, Elizabeth A Platz, Meir J Stampfer, Edward L Giovannucci, Christopher J Sweeney, Stephen P Finn, Lorelei A Mucci.

**A016 KDM4B promotes castration-resistant prostate cancer by regulating alternative splicing of the androgen receptor.** zhi-ping Liu.

**A017 Role of CHD1 in cistrome reprogramming and prostate cancer progression.** Michael A Augello, Lesa Deonarine, Deli Liu, Huang Dennis, Ashley Doane, Mark Rubin, Olivier Elemento, Andrea Sboner, Noah Dephoure, Christopher Barbieri.

**A018 Distinct Genomic Alterations in Prostate Cancer of African American Men.** Albert Dobi, Gyorgy Petrovics, Hua Li, Denise Young, Shyh-Han Tan, Yongmei Chen, Qingyu Xiao, Yidi Sun, Hong Li, Yixue Li, Yuan Ji, Jun Hou, Wendy Wang, Jacob Kagan, Guo-Ping Zhao, Sudhir Srivastava, Reinhard Ebner, Inger L Rosner, Jennifer Cullen, Matthew Freedman, Isabell Sesterhenn, Zoltan Szallasi, Shiv Srivastava.

**A019 HEME-OXYGENASE 1 DRIVES THE METABOLIC FATE IN PROSTATE CANCER.** Valeria G Antico Arciuch, Florencia Cascardo, Florencia Velazquez, Sofia Lage Vickers, Nicolas Anselmino, Estefania Labanca, Javier Cotignola, Geraldine Gueron, Nora Navone, Elba Vazquez.

**A020 Integrative analysis of the proteome in primary and advanced prostate cancer.** Leena Latonen, Ebrahim Afyounian, Antti Jylhä, Janika Nättinen, Ulla Aapola, Matti Annala, Kati Kivinummi, Teuvo Tammela, Roger W Beuerman, Hannu Uusitalo, Matti Nykter, Tapio Visakorpi.

- A021 CPT1A-mediated fat oxidation and its role in the immune response to prostate cancer.** Amanda M. Guth, Maren Salzmann-Sullivan, Camille Beaton, Amir Goldkorn, Emily A. Gibson, Elizabeth Kessler, Elaine Lam, Thomas Flaig, Rajesh Agarwal, [Isabel R. Schlaepfer](#).
- A022 Role of metallothionein in the pathogenesis of prostate cancer.** Sobia Hamid, [Mariam Anees](#).
- A023 Regulation of ERG function in prostate cells by phosphorylation and interaction with Ewing's sarcoma breakpoint protein EWS.** Vivekananda Kedage, Taylor R Nicholas, Brady G Strittmatter, Nagarathinam Selvaraj, Justin A Budka, Travis J Jerde, [Peter C Hollenhorst](#).
- A024 Prostate cancer neoadjuvant intensive androgen deprivation therapy selects for tumor foci with diverse oncogenic alterations.** [Adam G. Sowalsky](#), Huihui Ye, Manoj Bhasin, Eliezer M. Van Allen, Massimo Loda, Rosina T. Lis, Laleh Montaser, Carla Calagua, Fen Ma, Joshua W. Russo, Rachel J. Schaefer, Olga S. Voznesensky, Zhenwei Zhang, Glenn J. Buble, Robert B. Montgomery, Elahe A. Mostaghel, Peter S. Nelson, Mary-ellen Taplin, Steven P. Balk.
- A025 Unphosphorylated STAT1 dependent interferon signaling confers resistance to androgen deprivation therapy in advanced prostate cancer (CRPC).** [Supreet Agarwal](#), Kerry McGowen, Fathi Elloumi, Maggie Cam, Mike Beshiri, Keith Jansson, Eva Corey, Kathleen Kelly.
- A026 Expression of fibroblast growth factor receptor 1 isoforms and activation of different pathways in prostate cancer progression.** [Estefania Labanca](#), Jun Yang, Peter Shepherd, Justin Roberts, Michael Starbuck, Bradley Broom, Matthew Iyer, Christopher Logothetis, Arul Chinnaiyan, Nora Navone.
- A027 A novel two-step tumor cell isolation system, combining acoustophoresis and negative selection of white blood cells using CD45-conjugated elastomeric particles.** [Cecilia Magnusson](#), Eva Undvall, Thomas Laurell, Hans Lilja.
- A028 In vitro and in vivo efficacy of the androgen receptor antagonist darolutamide in prostate cancer models.** Tatsuo Sugawara, Simon J Baumgart, Kristin Reichert, Pascale Lejeune, [Bernard Haendler](#).
- A029 Targeting Neural Transcription Factor BRN2 in Neuroendocrine Prostate Tumors.** [Ravi Shashi Nayana Munuganti](#), Daksh Thaper, Amina Zoubeidi.
- A030 Systematic optimization of multiplex immunofluorescence of bone marrow eliminates false positives in the detection of disseminated tumor cells.** Haley Axelrod, Kenneth J Pienta, [Kenneth C Valkenburg](#).
- A031 Androgen deprivation therapy-induced TGFBI signaling promotes EMT and bone metastasis of prostate cancer.** [Yen-Nien Liu](#), Wei-Yu Chen, Yuan-Chin Tsai, Hsiu-Lien Yeh, Florent Suau, Jiaoti Huang.
- A032 miR-205 reconstitution sensitizes prostate cancer cells and xenografts to radiotherapy, through PKCε suppression.** [Paolo Gandellini](#), Rihan El Bezawy, Marco Folini, Denis Cominetti, Stella Tinelli, Tiziana Rancati, Riccardo Valdagni, Nadia Zaffaroni.
- A033 Identity fraud: Lineage plasticity as a mechanism of anti-androgen resistance and target for therapy.** [Alastair Davies](#), Chiara Bostock, Musaddeque Ahmed, Yen-Yi Lin, Fraser Johnson, Ka Mun Nip,

Kirsi Ketola, Jennifer Bishop, Ladan Fazli, David Goodrich, Faraz Hach, Hansen He, Himisha Beltran, Amina Zoubeidi.

**A034 PTEN status adds to CAPRA-S in predicting outcome after radical prostatectomy.** Andrew Erickson, Kanerva Lahdensuo, Irena Saarinen, Heikki Seikkula, Peter J Boström, Pekka Taimen, Antti Rannikko, Tuomas Mirtti.

**A035 Androgen receptor pathway inhibitor (ARPI) induced tumor dormancy and immune evasion.** Daksh Thaper, Paul Ahn, Amina Zoubeidi.

**A036 Blocking DNA and RNA synthesis by targeting glutamine metabolism in prostate cancer.** Qian (Kevin) Wang, Michelle van Geldermalsen, Angel Pang, Blake Zhang, Jeff Holst.

**A037 C1orf116, a gene of unknown function, promotes tight junctions and epithelial cell phenotype in prostate cancer.** Sarah R Amend, James Hernandez, Princy Parsana, Kenneth J. Pienta.

**A038 uPA/uPAR/MMP9 signaling hindered by heme oxygenase-1 in prostate cancer: Impact on cell invasiveness.** Alejandra V Paez, Javier H Cotignola, Elba S Vazquez, Geraldine Gueron.

**A039 Arginyltransferase Ate1 Reduction Drives Prostate Cancer Metastasis.** Michael D Birnbaum, Ning Zhou, Kerry L Burnstein, Fangliang Zhang.

**A040 Targeting the prostate cancer stem cell niche with the STAT3 inhibitor galiellalactone.** Giacomo Canesin, Anne T Collins, Rebecka Hellsten , Norman J Maitland, Anders Bjartell.

**A041 LSD1 inhibition disrupts FOXA1-dependent AR cistrome.** Shuai Gao, Dong Han, Sujun Chen, Wanting Han, Housheng Hansen He, Steven P Balk, Changmeng Cai.

**A042 Modulation of translation regulation by N6-methyladenosine in prostate cancer.** Kellie A Cotter, Kate D Meyer, Matteo Benelli, Sandra Cohen, Samie Jaffrey, Francesca Demichelis, Mark Rubin.

**A043 Bypass kinase pathways lead to acquired CDK4/6 inhibitor resistance in prostate cancer.** Renee de Leeuw, Christopher M McNair, Matthew J Schiewer, Neermala P Neupane, Michael A Augello, Zhen Li, Larry Cheng, Akihiro Yoshida, J Alan Diehl, E Starr Hazard, Sean M McCourtney, Gary Hardiman, Maha H Hussain, Justin M Drake, Wm Kevin Kelly, Karen E Knudsen.

**A044 Patient Derived Organoids to Model Neuroendocrine Prostate Cancer.** Loredana Puca, Rohan Bareja, Davide Prandi, Reid Shaw , Matteo Benelli , Myriam Kossai , Dong Gao , Wouter Karthaus, Michael Sigueros, Joanna Cyrta , Verena Sailer , Chantal Pauli, Scott T. Tagawa, David M. Nanus , Juan Miguel Mosquera, Charles L. Sawyers , Yu Chen, Giorgio Inghirami, Carla Grandori , Andrea Sboner , Francesca Demichelis, Mark A. Rubin , Himisha Beltran .

**A045 All happy families are alike: Transcriptomic homogeneity in indolent prostate tumors is a useful prognostic biomarker.** Travis Gerke, Svitlana Tyekucheva, Jordan H Creed, Kathryn L Penney, Jennifer A Sinnott, Ericka Ebot, Anders E Berglund, Massimo Loda, Meir J Stampfer, Peter Kraft, Giovanni Parmigiani, Lorelei A Mucci.

**A047 ONECUT2 is a targetable master regulator of aggressive variants of castration-resistant prostate cancer.** Mirja Rotinen, Sungyong You, Julie Yang, Simon Coetzee, Wen-Chin Huang, Fangjin Huang, Xinlei Pan, Alberto Yáñez, Dennis Hazelett, Chia-Yi Chu, Leland Chung, Stephen Freedland, Dolores Di Vizio, Isla Garraway, Ramachandran Murali, Beatrice Knudsen, Michael Freeman.

**A048 Bone remodeling in relation to androgen receptor activity in prostate cancer bone metastases.** Erik Bovinder Ylitalo, Annika Nordstrand, Elin Thysell, Emma Jernberg, Sead Crnalic, Anders Widmark, Anders Bergh, Ulf H. Lerner, Pernilla Wikström.

**A049 Centrosome loss and chromosomal instability in prostate tumor progression.** Mengdie Wang, Beatrice S Knudsen, Gregory C Rogers, Anne E Cress.

**A050 Integrated system-level analyses define an androgen receptor variant oncogenic network for advanced prostate cancer.** Fiorella Magani, Eric Bray, Maria Julia Martinez, Valeria Copello, Ning Zhao, Stephanie Peacock, David Wiley, Gennaro D'urso, Kerry L. Burnstein.

**A051 Liquid biopsy by Apheresis: Molecular characterisation of circulating tumor cells and their organoid culture reflects intra-patient heterogeneity and clonal evolution.** Maryou BK Lambros, Veronica Gil, Mateus Crespo, mariane S Fontes, Alan Mackay, Gemma Folwer, Gemma Folwer, Berni Ebbs, Rui Neves, Penny Flohr, Susana Miranda, Semini Sumanasuriya, Daniel N Rodrigues, Rita Pereira, Geroge Seed, Wei Yuan, Joanne Hunt, Deirdre Moloney, Dionne Ayanda, Niven Mehra, Jane Goodall, Claudia Bertan, Suzanne Carreira, Nikolas H Stoecklein, Leon W.M.M. Terstappen, Gunther Boysen, Joahnn S. De Bono.

**A052 Combining metabolic starvation and PI3K/AKT/mTOR pathway inhibition to chemosensitize prostate cancer cells.** Annamaria Bevilacqua, Angela Calastretti, Giuliana Gatti, Gianfranco Canti.

**A053 Targeting Akt1-beta catenin pathway in the advanced prostate cancer regulates tumor and vascular reciprocity and promotes cancer metastasis.** Abdulrahman M. Alwhaibi, Fei Gao, Payaningal R. Shenoy.

**A054 Loss of an androgen-inactivating and isoform-specific HSD17B4 splice form enables emergence of castration-resistant prostate cancer.** Hyun-Kyung Ko, Michael Berk, Yoon-Mi Chung, Belinda Willard, Rohan Bareja, Mark Rubin, Andrea Sboner, Nima Sharifi.

**A055 Racial Disparities in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Evidence from the Veteran's Health Administration (VHA).** Ahmad Halwani, Kelli M Rasmussen, Vikas Patil, Zachary Burningham, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie N Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C Sauer.

**A056 Is non-mutated GPR89A protein a potential drug target in prostate cancer?.** Yuanjun Ma, Yanling Liu, Sten Nilsson, Chunde Li.

**A057 Examining the link between obesity, inflammation and exercise in patients with metastatic prostate cancer - An interim analysis from the ExPeCT trial.** Lauren Brady, Grainne Sheill, Anne-Marie Baird, Emma H Allott, Tatjana Vlajnic, John Greene, Orla Casey, Brian Hayes, Emer Guinan, Juliette Hussey, Fidelma Cahill, Mieke Van Hemelrijck, Nicola Peat, Sarah Rudman, Moya Cunningham, Liam Grogan, Thomas Lynch, Rustom P Manecksha, John McCaffrey, Orla Sheils, Dearbhaile M O'Donnell,

John O'Leary, Ray McDermott, Stephen P Finn.

**A058 Integrative prostate cancer tissue proteomics dissects clear and distinct proteomes for human prostate cancer and benign prostatic hyperplasia.** [Sofia Lage Vickers](#), Juan Antonio Bizzotto, Alejandra Paez, Javier Cotignola, Carlos Scorticati, Osvaldo Mazza, Pia Valacco, Geraldine Gueron, Elba Vazquez.

**A059 Lifestyle and Health Related Quality of Life in Men with Metastatic Prostate Cancer.** [Gráinne Sheill](#), Lauren Brady, Emer Guinan, Juliette Hussey, David Hevey, Tatjana Vlajnic, Orla Casey, Anne-Marie Baird, Fidelma Cahill, Mieke Van Hemelrijck, Nicola Peat, Sarah Rudman, Thomas Lynch, Rustom P Manecksha, Brian Hayes, Moya Cunningham, Liam Grogan, John McCaffrey, Dearbhaile M. O'Donnell, Ray McDermott, John O Leary, Stephen P. Finn.

**A060 Repression of microRNA-338/421 by EZH2 represents a novel mechanism for SPINK1-positive prostate cancers.** [Vipul Bhatia](#), Anjali Yadav, Ritika Tiwari, Shivansh Nigam, Apul Goel, Bushra Ateeq.

**A062 Systemic Oncolytic Virotherapy for Prostate Cancer.** Tien Nguyen, [Michael A Barry](#).

**A063 Preclinical Evaluation of an Arginine Vasopressin Receptor 1A (AVPR1A) Antagonist in Castration-Resistant Prostate Cancer.** [Ning Zhao](#), Stephanie Peacock, Chen Hao Lo, Laine Heidman, Fiorella Magani, Meghan Rice, Ann Greene, Yushan Zhang, Yehia Daaka, Conor Lynch, Kerry Burnstein.

**A064 Mass Spectrometry-Based proteomics study makes Apolipoprotein E a potential risk factor for prostate cancer.** [Juan Bizzotto](#), Sofia Lage Vickers, Alejandra Paez, Carlos Scorticati, Javier Cotignola, Pia Valacco, Osvaldo Mazza, Elba Vazquez, Geraldine Gueron.

**A065 MicroRNA-338-5p/-421 mediated regulation of oncogenic long non-coding RNA MALAT1 abrogates Prostate cancer progression and metastases.** [Anjali Yadav](#), Vipul Bhatia, Ritika Tiwari, Shivansh Nigam, Apul Goel, Bushra Ateeq.

**A066 Rb and ZBTB7A cooperatively mediate the transcriptional repression function of androgen receptor.** [Wanting Han](#), Dong Han, Sujun Chen, Shuai Gao, Housheng He, Changmeng Cai.

**A067 Targeting the bromodomain and extra-terminal (BET) family proteins and beyond in metastatic castration resistant prostate cancer (mCRPC): Overcoming aberrant androgen receptor (AR) signaling.** [Adam Sharp](#), Jon Welti, Wei Yuan, Ines Figueiredo, veronica Gil, Daniel Nava Rodrigues, Maryou Lambros, Eleanor Knight, Jian Ning, Jeff Francis, David Dolling, Lorna Pope, Antje Neeb, Gunther Boysen, Yezi Zhu, Mateus Crespo, Alec Paschalis, Jun Luo, Stephen Plymate, Bissan Al-Lazikani, Amanda Swain, Johann de Bono.

**A068 Metabolic Signature in Lethal VS non-Lethal Prostate Cancer.** [Eugenio Zoni](#), Achim Buck, Annette Feuchtinger, Martin Spahn, Axel Walch, Marianna Kruithof-de Julio.

**A069 Combination of immune status and tumor microvascularisation provides strong prognostic markers for prostate cancer recurrence prediction.** Nathalie Harder, Maria Athelougou, Harald Hessel, Alexander Buchner, Christian Stief, Thomas Kirchner, [Günter Schmidt](#), Ralf Huss.

**A070 Targeting N-myristoyltransferase 1 inhibits prostate cancer progression.** [Omar Alsaidan](#), Sungjin Kim, Octavia Goodwin, Qianjin Li, Aiping Bai, Alicja Bielawska, George Zheng, Iryna Lebedyeva,

Thomas Albers, James S. Norris, Scott D. Pegan, Houjian Cai.

**A071 PSMA-specific CARTyrin T-Stem Cell Memory Therapy Eliminates Solid Tumor in Subcutaneous Prostate Cancer Model.** [Jenessa Barbara Smith](#), Rebecca Codde, Yening Tan, Barnett E. Barnett, David Hermanson, Srinivas Rengarajan, Eric M. Ostertag, Devon J. Shedlock.

**A072 Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer post-radiotherapy: a post-hoc analysis of the PR.7 trial.** [Paul Toren](#), Azik Hoffman, Keyue Ding, France-Hélène Joncas, Frédéric Pouliot, Yves Fradet, Éric Lévesque, Chantal Guillemette, Laurence Klotz.

**A073 Metabolism of saturated fatty acids accelerates Src-mediated prostate tumor progression.** [SUNGJIN KIM](#), Xiangkun Yang, Qianjin Li, Meng Wu, Zanna Beharry, Michael Bartlett, Alicja Bielawska, Houjian Cai.

**A074 Aberrant activation of a gastrointestinal transcriptional circuit in prostate cancer mediates castration resistance.** [Shipra Shukla](#), Joanna Cyrta, Devan Murphy, Edward Walczak, Leili Ran, Praveen Agrawal, Yuanyuan Xie, Yuedan Chen, Shangqian Wang, Yu Zhan, Wai Pung E Wong, Andrea Sboner, Himisha Beltran, Juan-Miguel Mosquera, Jessica Sher, Zhen Cao, John Wongvipat, Richard P Koche, Anuradha Gopalan, Deyou Zheng, Mark Rubin, Howard I Scher, Ping Chi, Yu Chen.

**A075 Bcl-2 family proteins as drug targets; Can prostate cancer be primed for apoptosis?.** [Kaitlyn Walsh](#), Rachel Wilson, Mary E McManamy, Victoria Del Gaizo Moore.

**A076 Tumor-Specific AR-HOXB13 Regulated Genes Reveal a Mitotic Protein-Protein Kinase Interaction Network Predictive of Metastatic Prostate Cancer.** [Kiran Mahajan](#), Yunyun Chen, Jiqiang Yao, Alexey Eroshkin, Ranjan Perera, Subramaniam Shyamalagovindarajan, Niveditha Nerlakanti, Ami Patel, Neha Agarwal, Jasreman Dhillon, Duy Nguyen, Jamie Teer, Zhenjun Ma, Youngchul Kim.

**A077 Chromatin state alterations in human prostate cancer progression.** [Joonas Tuominen](#), Tomi Häkkinen, Matti Annala, Kati Kivinummi, Teuvo Tammela, Leena Latonen, Kirsi Granberg, Tapio Visakorpi, Matti Nykter.

**A078 Towards understanding non-canonical phosphatidylinositol kinases in the maintenance of prostate metabolism.** [Joanna Triscott](#), Matteo Benelli, Verena Sailer, Davide Prandi, Brooke Emerling, Francesca Demichelis, Lewis Cantley, Mark A. Rubin.

**A079 MicroRNA-139 regulates prostate cancer aggressiveness by targeting IGF1R.** [Yutaka Amemiya](#), Christopher J Wallis, Tania Benatar, Elizabeth Kobylecky, Linda Sugar, Christopher Sherman, Robert Nam, Arun K Seth.

**A080 Caveolin-1 detected in tumor-derived exosomes induces cancer stem cell phenotypes in castration resistant prostate cancer.** [Chun-Jung Lin](#), Andrew Dang, Elizabeth Hernandez, Jer-Tsong Hsieh.

**A081 Activation of Sphingosine Kinase 1 by Lipopolysaccharide Promotes Prostate Cancer Cell Invasion via Matriptase.** [Cheng-Fan Lee](#), Benjamin Chen, Jer-Tsong Hsieh, Ming-Shyue Lee.

**A082 Mast cells- derived osteopontin protect from neuroendocrine differentiation of prostate cancer.** Elena Jachetti, Valeria Cancila, Claudia Enriquez, Ivano Arioli, Claudio Tripodo, Mario P Colombo.

**A083 Cell adhesion to laminin, by integrin  $\alpha 6\beta 1$ , mediates drug resistance to PI3K in castration resistant prostate cancer through AR-dependent induction of BNIP3.** Eric Nollet, Sourik Ganguly, Veronique Schulz, Eva Corey, Cindy K Miranti.

**A084 Reprogramming of Androgen Receptor Gene Expression by ACK1/TNK2 Mediated Histone H4 Tyr88-phosphorylation Promotes Castration Resistance.** Nupam Mahajan, Kiran Mahajan, Harshani Lawrence, Nicholas Lawrence.

**A085 Identification of circulating miRNAs associated with disease reclassification in prostate cancer patients on active surveillance.** Paolo Gandellini, Tiziana Rancati, Chiara Ciniselli, Mara Lecchi, Cristina Marengi, Elisa Campi, Paolo Verderio, Riccardo Valdagni, Nadia Zaffaroni.

**A086 Immunohistochemistry using anti-p504s antibody in prostate cancer: Comparison of novel and on-market antibody clones.** Ryan Miller, Carol Jones, Matthew Buckwalter, Katerina Dvorak.

**A087 Enzalutamide-induced hypoxia attenuates response and promotes resistance to Enzalutamide in pre-clinical models of prostate cancer.** Pamela J Maxwell, Melanie McKechnie, Oisin Duddy, Christopher W Armstrong, Judith M Manley, Chee Wee Ong, Jenny Worthington, Elena Deryugina, James P Quigley, Amina Zoubeidi, David J.J. Waugh, Melissa J LaBonte.

**A088 Tristetraprolin Is a Prognostic Biomarker for Poor Clinical Outcomes among Patients with Low-Grade Prostate Cancer.** Robert J Rounbehler, Anders E Berglund, Travis Gerke, Mandeep Takhar, Shivanshu Awasthi, Weimin Li, Elai Davicioni, Nicholas Erho, Ashley E Ross, Edward M Schaeffer, Eric A Klein, R. Jeffery Karnes, Robert B Jenkins, John L Cleveland, Jong Y Park, Kosj Yamoah.

**A089 Challenging the free hormone hypothesis for vitamin D in the prostate has implications for the prostate cancer disparity in African American men.** Zachary Richards, Larisa Nonn.

**A090 Targeting androgen receptor (AR) variants in castration resistant prostate cancer (CRPC) with a cancer specific theranostic agent.** Rey-Chen Pong, Bing Guan, Bin Wang, Guiyang Hao, Xiankai Sun, Yi-Qiang Cheng, Jer-Tsong Hsieh.

**A091 Therapeutic targeting of the p300/CBP bromodomain for the treatment of castration resistant prostate cancer.** Nigel Brooks, Neil Pegg, Jenny Worthington, Barbara Young, Amy Prosser.

**A092 Overcoming Tumor Immunity in Prostate Cancer by Targeting TAM Kinase Signaling.** . Lin Wang, Andriy Kobryn, Seonghee Joy Park, David J Mulholland.

**A094 The study of Single Nucleotide Polymorphisms (SNPs) of tumour suppressor gene in prostate cancer patient of Bangladeshi population.** Hasnain Imtiaz, Sharmin Afroz, Md. Amir Hossain, Sm Faysal Bellah, Md. Mustafizur Rahman.

**A095 Synthesis and Evaluation of Structure-Activity Based Derivatives of ERGi-USU, a Selective Inhibitor for ERG Positive Prostate Cancer Cells.** Ahmed A Mohamed, Charles P Xavier, Gauthaman Sukumar, Shyh-Han Tan, Lakshmi Ravindranath, Taduru L Sreenath, David G McLeod, Inger L Rosner,





**Poster Session B**

**Monday, December 4, 2017**

**12:30 p.m. – 2:30 p.m.**

**Salons IV-VI & Marvin Gardens and Marvin Gardens Patio**

**B001 CYP3A5 promotes AR downstream signaling and contributes to therapeutic resistance.** Priyatham Gorjala, Oscar B Goodman Jr., Ranjana Mitra.

**B002 CHD1 as a therapeutic target for prostate cancer.** Y. Alan Wang, Di Zhao, Ron dePinto.

**B003 NRH:Quinone Oxidoreductase 2 (NQO2) and Glutaminase (GLS) both play a role in large extracellular vesicles (LEV) formation in preclinical LNCaP-C4-2B prostate cancer model of progressive metastasis.** Thambi Doraj, Ankeeta B Shah, Faith Summers, Rajamma Mathew, Jing Huang, Tze-chen Hsieh, Joseph M Wu.

**B004 A combination of two chemically distinct inhibitors of class I HDACs is highly effective to suppress AR signaling and in vivo growth of prostate cancer xenograft.** Guimei Tian, Iqbal Mahmud, Ryan Stowe, Yushan Zhang, Hamsa Thayek Purayil, William Roush, Yehia Daaka, Daqing Liao.

**B005 Ginger Consumption Inhibit  $\beta$ -arrestin-2 Expression and Functions in Melanoma and Prostate Cancer Cells.** Tonelia A Mowart, Timothy Adekoya, Nikia Smith, Tonya S Lane, Ricardo M Richardson.

**B006 Analysis of the interaction of Human Herpes Virus 8 and gp130 in prostate cancer risk.** Jill D Henning, Kathrine Kercher, Clareann H Bunker, Robert E Ferrel, Alan L Patrick, Frank J Jenkins.

**B007 Stemness features of prostate cancer cells induced by carcinoma-associated fibroblasts.** Muriel A Nuñez, Javier Cerda-Infante, Marianela Sánchez, Paula Sotomayor, Alejandro S Godoy, Viviana P Montecinos.

**B008 PMEPA1 Isoform Specific Regulation of Androgen and TGF beta Signaling in Prostate Cancer.** Hua Li, Shashwat Sharad, Lakshmi Ravindranath, Gyorgy Petrovics, Yongmei Chen, Alagarsamy Srinivasan, Inger Rosner, Albert Dobi, Shiv Srivastava.

**B009 Amalgamated c-MYC Activation and p53 Loss Drives Rapid Prostate Tumorigenesis and Lethal Epididymis Tumors in Ai-Myc Model.** Wei Wang, Yanling Meng, Bingning Dong, Feng Yang.

**B010 The past, current and future incidence rates and burden of metastatic prostate cancer in the United States.** Scott Kelly, William Anderson, Philip Rosenberg, Michael Cook.

**B011 Body mass index trajectories across the life course and smoking in relation to prostate cancer incidence and mortality: the NIH-AARP Diet and Health Study.** Scott Kelly, Hannah Lennon, Matthew Sperrin, Charles Matthews, Neal Freedman, Demetrius Albanes, Michael Leitzmann, Andrew Renehan, Michael Cook.

**B012 Histone demethylase JMJD1A promotes the generation of androgen receptor variant 7 (AR-V7) in prostate cancer cells.** Lingling Fan, Fengbo Zhang, Ladan Fazli, Martin Gleave, Xuesen Dong, [Jianfei Qi](#).

**B013 Combined molecular targeting Src and mTOR pathways to impair prostate cancer cell survival.** [Yao Dai](#), Dietmar W. Siemann.

**B014 Simulating prostate cancer stem cell dynamics to predict patient-specific sensitivity or resistance to intermittent androgen deprivation therapy.** Renee Brady, John Nagy, John Nagy, [Heiko Enderling](#).

**B015 Potential systemic effects of beta-blocker use in prostate cancer patients.** [Helene H Grytli](#), Haakon Ramberg, Peder R Braadland, Heidi K Nielsen, Ingrid J Guldvik, Kristin A Taskén.

**B016 MicroRNA drivers of TMPRSS2 fusion negative prostate cancer in African Americans.** Manjunath Siddappa, Jason White, Honghe Wang, Lara E Sucheston-Campbell, Clayton Yates, [Moray J Campbell](#).

**B017 PARP-1 and E2F1 collaborate to transcriptionally regulate DNA repair factor availability.** [Matthew J Schiewer](#), Amy Mandigo, Nicolas Gordon, Fangjin Huang, Sanchaika Gaur, George Zhao, Joseph Evans, Sumin Han, Theodore Parsons, Ruth Birbe, Peter McCue, Tapio Visakorpi, Ganesh Raj, Mark Rubin, Johann de Bono, Costas Lallas, Edouard Trabulsi, Leonard Gomella, Adam Dicker, Wm. Kevin Kelly, Beatrice Knudsen, Felix Feng, Karen E Knudsen.

**B018 A High-throughput screen identifies HSP90 inhibitors as potent therapeutics across multiple clinically-representative organoid models of advanced prostate cancer.** [Keith H. Jansson](#), John B. Tucker, Lauren E. Stahl, John K. Simmons, Caitlyn Fuller, Michael L. Beshiri, Supreet Agarwal, Yasmine Abbey, Lei Fang, Paul G. Hynes, Alilin Aian Neil, Jacob Cawley, Ross Lake, Crystal Tran, Caitlin M. Tice, JuanJuan Yin, Xiahu Zhang, Rajarshi Guha, Shelley Hoover, R. Mark Simpson, Holly Nguyen, Eva Corey, Craig J. Thomas, David Proia, Kathleen Kelly.

**B019 Secreted Protein Acidic and Rich in Cysteine (SPARC) and Fetuin-A Autoantibodies as Biomarkers in Sera of Prostate Cancer Patients: Potential Use in Diagnosis and Prognosis.** Anshu Rastogi, Andy J Martinez, Shyh-Han Tan, Ali Amina, Jennifer Cullen, Yongmei Chen, Gyorgy Petrovics, Albert Dobi, Lakshmi Ravindranath, Denise Young, Isabell A Sesterhenn, Jacob Kagan, Sudhir Srivastava, David G McLeod, Inger L Rosner, Shiv Srivastava, [Alagarsamy Srinivasan](#).

**B020 Exploring prostate progenitor compartment complexity as a route of targeting prostate cancer heterogeneity.** Joao D Barros-Silva, Douglas E Linn, Guoji Guo, Adnan Syed Ali, Ivana Steiner, Hubert Pakula, Garry Ashton, Noel W Clarke, Guo-Cheng Yuan, Stuart O Orkin, Zhe Li, [Esther Baena](#).

**B021 Pre-diagnostic serum metabolomic profiling of prostate cancer survival.** Jiaqi Huang, Alison Mondul, Stephanie Weinstein, Andriy Derkach, Xing Hua, Steve Moore, Joshua Sampson, [Demetrius Albanes](#).

**B022 Defining new drivers of castration-resistant prostate cancer.** En-chi Hsu, Meghan Rice, Rosalie Nolley, Abel Bermudez, Jiaoti Huang, Donna Peehl, Christian Kunder, Sharon Pitteri, James Brooks ,

Tanya Stoyanova.

**B023 Identification and Biochemical Validation of Piperlongumine as a Potent Therapeutic Against Neuroendocrine Prostate Cancer.** Kamlesh K Yadav, Khader Shameer, Jennifer A Stockert, Cordelia Elaiho, Ben Readhead, Shalini S Yadav, Joel Dudley, Ashutosh K Tewari.

**B024 Family history of prostate cancer and the incidence of ERG- and PTEN-defined prostate cancer.** Dana Hashim, Amparo G Gonzalez-Feliciano, Thomas U Ahearn, Andreas Pettersson, Lauren Barber, Claire H Pernar, Ericka M Ebot, Stephen Finn, Edward L Giovannucci, Rosina T Lis, Massimo Loda, Giovanni Parmigiani, Kathryn L Penney, Tamara Lotan, Philip W Kantoff, Lorelei A Mucci, Rebecca E Graff.

**B025 The proteome of prostate cancer bone metastases.** Diego Iglesias-Gato, Elin Thysell, Sead Crnalic, Matthias Mann, Anders Widmark, Anders Bergh, Amilcar Flores-Morales, Pernilla Wikström.

**B026 Axl may support dormancy of disseminated tumor cells by inducing cell clustering and decreasing proliferation of metastatic prostate cancer cells .** Haley D Axelrod, Kenneth C Valkenburg, Jessica L Hicks, Angelo M DeMarzo, Kenneth J Pienta.

**B027 CD117 Tyrosine Kinase Activation Drives Prostate Cancer Aggressiveness.** Lihong Shi, Brittni Foster, Koran Harris, Aleksander Skardal, Bethany A Kerr.

**B028 Comparative assessment of cellular functions for the ZBTB methyl-CpG binding proteins in prostate cancer.** Amir Pozner, Aneesa T. Al-Soodani, Sheryl Tripp, Justin Caron, Daniel J. Albertson, Bethany A. Buck-Koehntop.

**B029 Does coffee consumption confer survival benefits among men diagnosed with prostate cancer? A large prospective analysis in the Health Professionals Follow-up Study.** Cindy Zhou, Edward Giovannucci, Lorelei Mucci, Kathryn Wilson.

**B030 MEK5 downregulation enhances radiosensitization of human prostate cancer cells by inhibiting DNA repair.** Constantinos G. Broustas.

**B031 CREB1 and ATF1 differentially regulate terminal prostate luminal differentiation by controlling the timing of ING4 expression, while CREB1 prevents ING4 expression upon PTEN loss in prostate cancer.** McLane Watson, Penny Berger, Sander Frank, Mary Winn, Cindy Miranti.

**B032 Inappropriate AR reactivation-induced redox stress as a novel therapeutic target in castration-resistant prostate cancer.** Govindi J. Samaranayake, Clara I. Troccoli, Mai Q. Huynh, Rolando D.Z. Lyles, Deukwoon Kwon, Yuguang Ban, Steven Xi Chen, Merce Jorda, Kerry Burnstein, Priyamvada Rai.

**B033 Characterizing the global function of NCOR2 in prostate cancer cells and its contribution to PCA progression.** Mark D Long, Prashant K Singh, Gerard Llimos, Spencer Rosario, Dominic J Smiraglia, Moray J Campbell.

**B034 Time to Treatment and Overall Survival among Men with Localized Prostate Cancer.** Dudith Pierre-Victor, Paul Pinsky, Iman K Martin , Wortia McCaskill-Stevens.

**B035 Radio-resistance of PTEN-deficient prostate tumors is enhanced by treatment-induced chemokine signaling and is associated with biochemical recurrence and development of metastasis.** Chris W.D. Armstrong, Jonathan A. Coulter, Chee Wee Ong, Pamela J. Maxwell, Karl T. Butterworth, Oksana Lyubomska, Melissa J. LaBonte, Silvia Berlinger, Rebecca Gallagher, Steven M. Walker, Joe M. O'Sullivan, Suneil Jain, Ian G. Mills, Manuel Salto-Tellez, Timothy Illidge, Richard D. Kennedy, Kevin M. Prise, David J.J. Waugh.

**B036 Comprehensive transcriptomic profiling challenges the robustness of prostate cancer prognostic signatures to multifocality.** Simpa Salami, Daniel H Hovelson, Jeremy B Kaplan, Romain Mathieu, Aaron M Udager, Nicole Curci, Matthew Lee, Lorena Lazo de la Vega, Martin Susani, Nathalie Rioux-Leclercq, Daniel E Spratt, Todd M Morgan, Matthew S Davenport, Mark A Rubin, Shariat F Shahrokh, Scott A Tomlins, Ganesh S Palapattu.

**B037 N-Myc driven cell plasticity in castrate resistant prostate cancer.** Etienne Dardenne, Adeline Berger, Katie Gayvert, Loredana Puca, Jamal Elkader, Brian Robinson, Olivier Elemento, Beltran Himisha, David Rickman.

**B038 Convergent hormone therapy resistance mediated by stress/dormancy-like pathways in prostate cancer.** Kathryn E Ware, Santosh Gupta, Jared Eng, Wen-Chi Foo, Lorin Crawford, Garland Austin, Bhairavy Puvindran, Jennifer Freedman, Steven R Patierno, Tian Zhang, David Corcoran, Mariaelena Pierobon, Emanuel Petricoin, Jason A Somarelli, Andrew J Armstong.

**B039 Multinucleation precedes the emergence of drug resistance in prostate cancer.** Gonzalo Torga, Ke-Chih Lin, Robert H Austin, Kenneth J Pienta.

**B040 Differential impact of RB status on E2F1 reprogramming in human cancer.** Christopher McNair, Kexin Xu, Amy C Mandigo, Matteo Benelli, Benjamin Leiby, Daniel Rodrigues, Johan Lindberg, Henrik Gronberg, Mateus Crespo, Bram De Laere, Luc Dirix, Tapio Visakorpi, Fugen Li, Felix Y Feng, Johann de Bono, Francesca Demichelis, Mark A Rubin, Myles Brown, Karen E Knudsen.

**B041 Disease stage specific re-calibration of E2F1 function after RB loss .** Amy C Mandigo, Chris McNair, Kexin Xu, Fugen Li, Matthew J Schiewer, Myles Brown, Karen E Knudsen.

**B042 Genomic correlates of imaging response in men receiving intense neoadjuvant androgen deprivation therapy.** Scott Wilkinson, Huihui Ye, Rayann Atway, Shana Y Trostel, Nichelle C Whitlock, S. Thomas Hennigan, Ross Lake, Stephanie Harmon, Baris Turkbey, Peter A Pinto, Peter L Choyke, Fatima Karzai, William L Dahut, Kathleen Kelly, David J VanderWeele, Adam G Sowalsky.

**B043 Cancer stem cell selection drives adverse response to androgen deprivation therapy.** Kai Sha, Lingxiang Jiang, Chawnschang Chang, Dean Tang, Kent L Nastiuk, John J Krolewski.

**B044 ONC201 inhibits AR signaling pathway by upregulating ATF3.** Avital Lev, Amriti R Lulla, David T Dicker, Wafik S El-Deiry.

**B045 Gene expression pathways associated with vigorous physical activity in prostate cancer.** Claire H Pernar, Giovanni Parmigiani, Edward L Giovannucci, Eric B Rimm, Stephen Finn, Michelangelo Fiorentino, Ericka M Ebot, Lorelei A Mucci.

**B046 Circadian cryptochrome 1 (CRY1) modulates DNA damage response in prostate cancer.** [Ayesha A Shafi](#), Jennifer J McCann, Karen E Knudsen.

**B047 Biochemical parameters of prostate cancer patients in Nigeria.** [Emeka Iweala](#), Solomon Rotimi, Faith Kanu, Chidiebere Ogo.

**B048 Androgen metabolism and incidence of prostate cancer in Nigeria.** Solomon Rotimi, Chidiebere Ogo, Olubanke Ogunlana, Shalom Chinedu, [Emeka Iweala](#).

**B049 DNA damage echoes are key to prostate cancer susceptibility to supraphysiological androgen levels.** [Payel Chatterjee](#), Jared M Lucas, Michael D Nyquist, Eva Corey, Peter S Nelson.

**B050 The Role of Activated Beta-catenin/Wnt Signaling in the Progression of Castration Resistance of Prostate Cancer in Bone.** [Justin M. Roberts](#), Estefania Labanca, Peter Shepherd, Jun Yang, Michael W. Starbuck, Nora M. Navone.

**B051 PDX-derived and patient-derived prostate cancer organoids as a clinically relevant platform for translational research.** [Michael L Beshiri](#), Caitlin M Tice, Crystal Tran, Holly M Nguyen, Adam G Sowalsky, Supreet Agarwal, Keith H Jansson, Kerry McGowen, Aian Neil Alilin, JuanJuan Yin, Fatima H Karzai, William L Dahut, Eva Corey, Kathleen Kelly.

**B052 Leveraging the metabolic stress of polyamine biosynthesis in prostate cancer towards a novel therapeutic approach.** [Hayley C Affronti](#), Anthony J Pellerite, Aryn Rowsam, Spencer R Rosario, Robert A Casero, Mikhail A Nikiforov, James Phillips, Dominic J Smiraglia.

**B053 Estrogen receptor alpha coordinates homeostatic gene expression programs via translational buffering.** Julie Lorent, Vincent van Hoef, Mitchell G Lawrence, Yutian Cai, Itsuhiro Takizawa, Robert Nadon, Gail P Risbridger, Ivan Topisirovic, [Ola Larsson](#), Luc Furic.

**B054 Oncogenic convergence of normal human prostate epithelial cells to a small cell neuroendocrine phenotype.** [Jung Wook Park](#), Nikolas Balanis, Katherine M Sheu, Kim Nguyen, John K Lee, Jiaoti Huang, Thomas Graeber, Owen N Witte.

**B055 Optimized human monocyte-derived macrophage cultures accurately reflect macrophage immunomodulatory function.** [Amber E de Groot](#), Kenneth J Pienta.

**B056 GRK5 promotes a mesenchymal transition in prostate cancer.** [Joseph B Black](#), Hamsa Purayil, Iqbal Mahmud, Yehia Daaka.

**B057 A HIGHLY POTENT NOVEL CLASS OF P160-SRC INHIBITORS FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER.** [Salma Kaochar](#), Cristian Coarfa, Jin Wang, Bert O'Malley, Nicholas Mitsiades.

**B058 Genetic contribution of MYC to the development of primary prostate cancer.** [Nichelle C Whitlock](#), Rayann Atway, Qi Yang, Huihui Ye, Adam Sowalsky.

**B059 Integrated genomic analysis of coincident cancer foci highlights PTEN alterations enriched in ductal prostate adenocarcinoma.** [Jose Antonio Rodriguez-Nieves](#), Marc Gillard, Justin Lack, Adam

Sowalsky, Donald Vander Griend, Paner Gladell, David VanderWeele.

**B060 Molecular characterization of cancer stem cells from patient derived xenografts of advanced prostate cancer.** Sofia Karkampouna, Marta de Menna, Markus Germann, Jöel Grosjean, Peter C Gray, George N Thalmann, [Marianna Kruithof-de Julio](#).

**B061 Alternative RNA Splicing and Prostate Cancer Aggressiveness.** [Muthana Al Abo](#), Steven R Patierno, Jennifer A Freedman.

**B062 Proteomic characterization of the secretome from prostate cancer and bone progenitor cell co-culture.** [Nicolás Anselmino](#), Alejandra Páez, Sofía Lage Vickers, Javier Cotignola, Pía Valacco, Geraldine Gueron, Elba Vázquez.

**B063 Towards the use of Raman spectroscopy to guide prostate biopsy procedure.** [Kelly Aubertin](#), Mirela Birlea, Michael Pinto, Karl St-Arnaud, Vincent Quoc Trinh, Andrée-Anne Grosset, Frédéric Leblond, Dominique Trudel.

**B064 Genomic heterogeneity and molecular classification of multifocal prostate cancer.** [Marthe Løvf](#), Kristina Totland Carm, Sen Zhao, Ulrika Axcrona, Bjarne Johannessen, Anne Cathrine Bakken, Andreas M Hoff, Ola Myklebost, Leonardo A Meza-Zepeda, A Kathrine Lie, Karol Axcrona, Ragnhild A Lothe, Rolf I Skotheim.

**B065 Genomic analysis of localized prostate cancer identifies AZIN1 as driver of metastatic progression.** Thomas Van den Broeck, [Lisa Moris](#), Thomas Gevaert, Elien Smeets, Stefan Prekovic, Christine Helsen, Hendrik van Poppel, Wouter Everaerts, Christine Buerki, Elai Davicioni, Steven Joniau, Frank Claessens.

**B066 Development of paired small molecule drug conjugates for prostate cancer precision theranostics.** [Bing Guan](#), Yunkou Wu, Jingyue Yang, Yahong Xiong, Jer-Tsong Hsieh, Guiyang Hao, Xiankai Sun.

**B067 Neuropilin-2 is correlated with significantly shorter cancer specific survival in prostate cancer patients and is highly upregulated in bone metastases.** Angelika Borkowetz, Dutta Samishkan, Pia Hoenscheid, Susanne Fuessel, Kati Erdmann, Michael Froehner, Manfred Wirth, Kaustubh Datta, Gustavo Baretton, Marieta Toma, [Michael Muders](#).

**B068 Methionine Aminopeptidase II (MetAP2) Activated In Situ Self-Assembly of Small-Molecule Probes for Imaging Prostate Cancer.** [Jinghang Xie](#), Meghan Rice, Yunfeng Cheng, Guosheng Song, Christian Kunder, James D Brooks, Tanya Stoyanova, Jianghong Rao.

**B069 Drug response variability between luminal and basal prostate cancer tumors.** Robert Den, Jonathan Lehrer, Mandeep Takhar, Mohammed Alshalalfa, [Nicholas Erho](#), Elai Davicioni, Felix Feng.

**B070 Epithelial-marker absent and disease-marker specific circulating and disseminated tumor cells are rarely detected in men with localized prostate cancer.** [Stephanie Glavaris](#), Heather Chalfin, Changxue Lu, Yan Chen, Emily Caruso, Kenneth Valkenburg, Jun Luo, Kenneth Pienta.

**B071 Circulating tumor cells as liquid biopsies of skeletal metastases from prostate cancer.** [Andreas](#)

Josefsson, Karin Larsson, Daniel Åhs, Helena Brisby, Jan-Erik Damber, Karin Welén.

**B072 Predicting prostate cancer susceptibility with polygenic risk scores.** Lindsay N Sauville, Fredrick R Schumacher.

**B073 Stat5a/b Blockade Sensitizes Prostate Cancer to Radiation Through Inhibition of Rad51 and DNA Repair.** Cristina Maranto, Vindhya Udhane, Ayush Dagvadorj, David T. Hoang, Lei Gu, Vitali Alexeev, Kareem Malas, Karmel Cardenas, Mateusz Koptyra, Jonathan R Brody, Ulrich Rodeck, Carmen Bergom, Ken A Iczkowski, Ken Jacobsohn, William See, Sara M. Schmitt, Marja T. Nevalainen.

**B074 Stem cell directed pan cancer analysis reveals a human adult stem cell signature that defines aggressive epithelial cancer subtypes.** Bryan A Smith, Nikolas G Balanis, Avinash Nanjundiah, Katherine M Sheu, Qingfu Zhang, Jung Wook Park, Michael Thompson, Jiaoti Huang, Thomas G Graeber, Owen N Witte.

**B075 The role of TET1 and hydroxymethylation in high-risk prostate cancer.** Elien Smeets, Lien Spans, Stefan Prekovic, Thomas Van den Broeck, Lisa Moris, Thomas Gevaert, Christine Helsen, Steven Joniau, Frank Claessens.

**B076 Osteoclasts influence androgen related gene expression in prostate cancer cells.** Junchi Huang, Jan-Erik Damber, Karin Welen.

**B077 3D reconstruction and machine learning based analysis of prostate cancer from histological images.** Pekka Ruusuvoori, Mira Valkonen, Kimmo Kartasalo, Tapio Visakorpi, Matti Nykter, Leena Latonen.

**B078 Expression of activated STAT3 in the epithelial cells of hormone-naïve prostate cancer.** Agnieszka Krzyzanowska, Nicholas Don-Doncow, Felicia-Elena Marginean, William Watson, Rebecka Hellsten, Anders Bjartell.

**B079 Prospective study on the use of Raman molecular imaging to determine postoperative oncological outcomes in patients with prostate cancer: Analysis of a single-center.** Arash Samiei, Ralph Miller, Jeffrey Cohen, Heather Gomer, Shona Stewart, Patrick Treado.

**B080 Heme-oxygenase 1 negatively regulates interferon inducible antiviral (mx1) in prostate cancer.** Emiliano Ortiz, Alejandra Páez, Nicolás Anselmino, Javier Cotignola, Pía Valacco, Elba Vázquez, Geraldine Gueron.

**B081 Clinically relevant molecular subgroups of prostate cancer bone metastases.** Elin Thysell, Erik Bovinder Ylitalo, Emma Jernberg, Sead Crnalic, Anders Widmark, Anders Bergh, Pernilla Wikström.

**B082 Osteolytic and osteoblastic prostate cancer cells remotely trigger different responses in the bone marrow niche.** Daniel Åhs, Andreas Josefsson, Jan-Erik Damber, Karin Welén.

**B083 Disease marker specific disseminated tumor cells in bone are rare at the time of radical prostatectomy.** Emily A Caruso, Stephanie Glavaris, Heather J Chalfin, Kenneth C Valkenburg, Mohamad E Allaf, Misop Han, Kenneth Pienta.

**B084 Trop-2 plasticity is driven by epithelial-to-mesenchymal transition in prostate cancer cells.** Ján Remšík, Lucia Binó, Zuzana Kahounová, Gvantsa Kharaishvili, Sarka Simeckova, Radek Fedr, Tereza Nehybova, Eva Slabáková, Lucia Knopfová, Jan Bouchal, Milan Kral, Petr Benes, [Karel Soucek](#).

**B086 Monocytes-produced Chitinase-3-like 1 is a driver of metastatic behavior in advanced prostate cancer patients.** Karen A Cavassani, [Rebecca Meza](#), David Habel, Jie-Fu Chen, Alexander Montes, Manisha Tripathi, Gislaine Martins, Timothy R Crother, Cory M Hogaboam, Sungyong You, Neil Bhowmick, Edwin Posadas.

**B087 A Phase I study to evaluate Next Generation DNA Sequencing Testing in rectal swabs prior to transrectal prostate biopsy for cancer screening and diagnosis.** [Vladimir Mouraviev](#), Michael W McDonald, Srinivas Vourganti, David M Albala, Florian M.E. Wagenlehner, Kurt Naber, Truls E. Bjerklund Johansen.

**B088 Analytical validation of a live-cell phenotypic biomarker - based diagnostic assay for the prediction of adverse pathology in prostate cancer from field biopsy cores.** [Vladimir Mouraviev](#), David M Albala, Michael S. Manak, Jonathan S. Varsanik, Grannum R. Sant, Ashock C. Chander.

**B089 Targeting of prostate cancer metabolism through the Liver X Receptor.** [Suomia Abuirqeba](#), Colin Flaveny, Sameer Siddiqui.

**B090 Personalized research: Establishment and Characterization of Prostate Cancer Patient-derived Organoids and Cells.** [Katia Anis Cheaito](#), Ola Hadadeh, Hisham Bahmad, Marwan El-Sabban, Albert El-Hajj, Deborah Mukherji, Wassim Abou-Kheir.

**B091 Small Molecule Inhibitors Targeting a Specific Metabolic Pathway for Precision Therapy of Advanced Castrate-Resistant Prostate Cancer.** [Hirak Basu](#), Nathaniel Wilganowski, Jessica Lieblich, Grace Wu, Izabela Fokt, Sumankalai Ramachandran, Jiaquin Yu, Mark Titus, Waldemar Priebe, David J Beebe, George Wilding.

**B092 Myokine signaling blockade prevents androgen deprivation therapy induced sarcopenia and promotes prostate tumor regression.** Chunliu Pan, Yanni Zulia, [Kent L. Nasituk](#).

**B093 Development and Validation of a Novel Automated Gleason Grade and Molecular Profile that Define a Highly Predictive Prostate Cancer Progression Algorithm-Based Test.** [Michael Joseph Donovan](#), Gerardo Fernandez, Richard Scott, Jack Zeineh, Giovanni Koll, Faisal Khan, Nataliya Gladoun, Elizabeth Charytonowicz, Ash Tewari, Carlos Cordon-Cardo.

**B094 Quantitative Digital Image Analysis and Machine Learning for Staging of Prostate Cancer at Diagnosis .** Fangjin Huang, Nathan Ing, Miller Eric, Hootan Salemi, Michael Lewis, Isla Garraway, Arkadiusz Gertych, [Beatrice Knudsen](#).

**B095 An automated tissue staining and quantitative digital image analysis pipeline for quantification of DNA damage repair at the single cell level.** [Joshua Saylor](#), Eric Weterings, Nathan Ellis, James Hinton, Esteban Roberts, Anne Cress, Beatrice Knudsen, Beatrice Knudsen, Beatrice Knudsen.

**B096 CDCP1, a potential non-invasive biomarker in circulating tumor cells for treatment of prostate cancer with FAK inhibitors.** [Sara Pollan](#), Jamie Sperger, Joshua Lang, Fangjin Huang, Jie Zheng, Colm



Morrissey, Anne E. Cress, Danislav Spassov, Mark Moasser, William Carter, Beatrice Knudsen.

**B097 NRF2 antioxidant signaling mediates the ability of PIM protein kinases to induce resistance of prostate cancer to PI3K inhibitor therapy.** Jin H Song, Libia A Leuvano, Neha Singh, Andrew S Kraft.

**B098 Genomic variations associated with prostate cancer in large cohort of African American men.** Walter Rayford, Jennifer Jordan, Mandeep Takhar, Mohammed Alshalalfa, Darlene Dai, Nicholas Erho, Mark D. Greenberger, Elai Davicioni.

**B099 3D Organoids from Milligrams of Patient Tissue Retain Key Features of Original Tumors.** Yue Joy Wang, Glauco R Souza, Robert R Amato.

**B100 High-risk pathological and genomic features of BRCA2-mutant prostate cancer.** Laura H Porter, Mitchell G Lawrence, Carmel Pezaro, Heather Thorne, Dragan Ilic, Melissa Papargiris, Michael Fraser, Julie Livingstone, Declan G Murphy, Mark Frydenberg, Damien Bolton, Daniel Moon, David Clouston, Theo van der Kwast, Paul C Boutros, Robert G Bristow, Renea A Taylor, Gail P Risbridger.

**B101 Prostate kallikrein (hK2) abrogates therapeutic efficacy of bivalent vaccine targeting PSA and PSCA antigens.** Seema Dubey, Dev Karan.